Histone deacetylases (HDACs) have been identified as therapeutic targets due to their regulatory function in chromatin structure and organization. Here, we analyzed the therapeutic effect of LBH589, a class I --II HDAC inhibitor, in acute lymphoblastic leukemia (ALL). In vitro, LBH589 induced dose-dependent antiproliferative and apoptotic effects, which were associated with increased H3 and H4 histone acetylation. Intravenous administration of LBH589 in immunodeficient BALB/ c-RAG2
INTRODUCTION
Although it is tempting to consider acute lymphoblastic leukemia (ALL) as a curable disease because of the remarkable improvement in the cure rates observed in recent years, the prognosis of relapsed patients is still dismal. 1 Almost 80% of children diagnosed with ALL become cured with modern risk-adapted therapies. However, 460% of adult patients will eventually relapse and most of them will succumb to their disease. This underlies the need for new therapeutic options for resistant patients. The role of recurrent chromosomal translocations in the pathogenesis of ALL has been clearly established 2 providing not only important prognostic information but also guiding the development of new treatments such as the use of tyrosinekinase inhibitors (imatinib or dasatinib) in patients with t(9;22). 3 Other genetic alterations such as the overexpression of FLT3 receptor tyrosine kinase in mixed-lineage leukemia gene-rearranged or hyperdiploid B-ALL 4 or the presence of NOTCH1-activating mutations in T-cell ALL are attractive candidates for targeted therapies with FLT3 or NOTCH inhibitors (g-secretase inhibitors). 5 Indeed, the current view of the pathogenesis of ALL suggests that several genetic lesions need to act in concert to induce overt leukemia. 1 The classical view of cancer as a genetic disease has been challenged by the clear demonstration that epigenetic modifications can alter gene expression by mechanisms that do not affect the DNA sequence itself. Epigenetics has an important role in the pathogenesis and prognosis of various tumors. The hypermethylation of DNA promoters and changes in histone modification patterns are the most frequently described abnormalities in tumor cells. 6 Along with others, we have extensively demonstrated that patients with ALL frequently show an abnormal hypermethylation of DNA promoter of tumor-suppressor genes, microRNAs (miRNAs) or genes involved in tumorigenic pathways such as WNT or Ephrin-Eph pathway, and that these changes are associated with prognosis of the disease. 7 --12 Among the various epigenetic modifiers, histone deacetylases inhibitors (HDACi) have emerged as promising drugs for the treatment of a number of tumors. 13 HDACis are a class of anticancer agents that inhibit deacetylation of histones and non-histone cellular proteins, inducing hyperacetylation and an 'open chromatin' configuration. In cancer, such hyperacetylation is associated with a greater transcriptional activity of silenced tumor-suppressor genes. LBH589 (also called Panobinostat) is an HDACi characterized as a pan-deacetylase inhibitor with activity against both class I and II HDACs. This drug has demonstrated a significant activity against different tumors such as myeloma, acute myelogenous leukemia and T-cell lymphomas as well as breast, prostate, colon and pancreatic cancer. 14, 15 In this study, we investigate the role of the HDACi LBH589 using in vitro and in vivo models of ALL, and demonstrate that treatment of ALL cells with LBH589 induces a prolonged survival in a mouse model of human ALL. Also, we show that this effect is significantly improved when combined with currently active drugs used to treat ALL, providing the basis for using this combination in patients with ALL.
MATERIALS AND METHODS

Human samples and cell lines
Six ALL-derived cell lines TOM-1, REH, 697, s.e.m., TANOUE and MOLT-4, were purchased from the DSMZ (Deutche Sammlung von Microorganismen und Zellkulturen GmbH, Braunschweig, Germany). Cell lines were maintained in culture in RPMI 1640 medium supplemented with 10% fetal bovine serum and with 1% penicillin --streptomycin and 2% HEPES (Gibco-BRL, Verviers, Belgium) at 37 1C in a humid atmosphere containing 5% CO 2 .
To generate the mouse model, bone marrow (BM) or peripheral blood (PB) mononuclear cells were obtained at diagnosis from patients with ALL after signed informed consent had been obtained from the patient or the patient's guardians, in accordance with the Declaration of Helsinki.
Reagent and cell drug treatment
The HDACi LBH589 was provided by Novartis Pharmaceuticals (East Hanover, NJ, USA) and diluted in saline solution for in vitro studies and in 5% dextrose (D5W) for in vivo experiments. Cell lines were treated with LBH589 at different concentration and maintained in culture for up to 4 days after which cells were washed in phosphate-buffered saline and used for different assays. The half maximal inhibitory concentration (IC 50 ) values was determined using GraphPad Prism log (inhibitor) vs response (variable slope) software (version 5, La Jolla, CA, USA).
Protein extraction and western blot
Protein extracts were separated by 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis, transferred onto a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA) and incubated with a monoclonal antibody against described proteins. A detailed description is included in the Supplementary Materials and methods.
Cell proliferation
Cell proliferation was analyzed after 24, 48, 72 and 96 h of in vitro treatment using the Celltiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA) as previously described. 8 All experiments were repeated three times.
Apoptosis assays
Apoptosis induction was analyzed using the ELISAPLUS 10 Â Cell Death Detection Kit (Roche, Mannheim, Germany), following the manufacturer's instructions, the FITC-Conjugated Monoclonal Active Caspase-3 Antibody Apoptosis Kit (BD Pharmingen, San Diego, CA, USA), and by detection of the 85 kDa fragment of poly(ADP ribose)polymerase. 8, 16 Single-nucleotide polymorphism chip analysis DNA from primary cells and tissues was extracted using QIAmp DNA Mini Kit following the manufacturer's instructions (Qiagen, Hilden, Germany). DNA was quantified using NanoDrop Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). DNA from samples was analyzed on Affymetrix GeneChip Human mapping 250K SNP arrays (Santa Clara, CA, USA) capable of genotyping on average 250 000 singlenucleotide polymorphisms according to the manufacturer's protocol. Microarray data were analyzed for determination of both total and allelic-specific copy numbers using the Genotyping Console software (Affymetrix, Santa Clara, CA, USA) as previously described. 17 DNA methylation array analysis A HumanMethylation27 BeadChip (Illumina, Inc., San Diego, CA, USA) was used to quantify DNA methylation. The panel is developed to quantify the methylation status of 27 578 CpG sites located within the proximal promoter of 14 475 well-annotated genes from the consensus coding sequence project as well as known cancer genes and miRNAs. The protocol was performed according to the manufacturer's instructions. The methylation status of a CpG was determined by the beta value calculation, which ranges from 0 for unmethylated CpGs to 1 for completely methylated CpGs.
Gene expression array analysis
Total RNA from primary cells and tissues was extracted with Ultraspec (Biotecx, Houston, TX, USA) following the manufacturer's instructions after tissue lysates were prepared using a mechanical tissue homogenization by ultraturrax (IKA, Wilmington, DE, USA). RNA was quantified using NanoDrop Specthophotometer (NanoDrop Technologies). Gene expression analysis was performed using GeneChip Human Gene 1.0 ST array (Affymetrix) following the manufacturer's instructions. Microarray data were normalized and analyzed as previously described. 18 TaqMan low-density arrays A TaqMan Low-Density Array A v2.1 (Applied Biosystems, Foster City, CA, USA) was used for 377 human miRNA expression assays after treatment. A total concentration of 500 ng of RNA was used for the array hybridization. Reverse transcription and real-time PCR reactions were done following the manufacturer's instructions without product pre-amplification.
Bioinformatic data analysis
A detailed description of the bioinformatic data analysis is provided in the Supplementary Materials and methods. Raw array data files were submitted to GEO (Gene Expression Omnibus) and are available under the accession number GSE26807.
In vivo experiments
All animal studies had previous approval from the Animal Care and Ethics Committee of the University of Navarra, whereas experiments that used patient samples were approved by the Human Research Ethics Committees of University of Navarra. For the human subcutaneous ALL model, 6-week-old female BALB/cA-RAG2 À/À gc À/À mice were subcutaneously inoculated in its back left flank with 1 Â 10 6 human ALL viable cells in 100 ml volume of saline solution. At least eight mice were included in each group. A group of healthy control BALB/cA-Rag2 À/À gc À/À mice was treated with increasing doses of LBH (1, 5, 10 and 20 mg/kg). Doses were selected based on previously published studies 19 and administered intraperitoneally (i.p.) to determine the maximum tolerated dose of LBH589. Treatment was initiated 24 h after injection of leukemic cells and included three cycles of 5 consecutive days of LBH589 with 2 days rest between cycles. Tumor size was analyzed every 3 days using the following method:
, where D and d corresponding to the longest and shorter diameter, respectively. Mice were killed 24 days after cell inoculation or when their tumor diameter reached 17 mm.
Two human ALL xenograft mice models were generated by intravenously (i.v.) injection of 10 Â 10 6 human primary cells diluted in 100 ml of saline solution in the tail vein of a 6-week-old female BALB/cA-RAG2 
Fluorescence-activated cell sorting analysis
For immunephenotyping, 50 --100 ml of PB, BM or 500 000 human blasts from mice spleen were isolated by Ficoll --Paque plus (GE Healthcare). Cells were labeled for 15 min with the following antibodies: rat anti-mouse CD45-PE (BD Pharmingen), mouse anti-human CD5-APC (BD Pharmingen) mouse anti-human CD45-PerCP (BD Pharmingen), mouse anti-human CD22-PE (BD Pharmingen) followed by 10-min incubation with 2 ml of fluorescence-activated cell sorting lyses solution (1:10) (Becton Dickinson, San Jose, CA, USA). Cells were washed with saline solution and centrifuged at 600 g for 7 min. The supernatant was decanted and cells were fixed in 400 ml of 0.4% paraformaldehide. The analysis was done with FACSCalibur cytometer and Paint-A-Gate software (Becton Dickinson).
Histological and immunochemistry analysis
Organs collected from mice were fixed in paraformaldehyde at 4% for 6 --8 h and washed twice with saline solution and stored in 70% ethanol. Samples were included in paraffin and 3 mm serial sections were cut, deparaffinated and stained with hematoxilin --eosin. For the immunohistochemical characterization, deparaffinated slides were heat treated using high or low pH solution (target retrieval solution low pH, En Vision FLEX, Dako, Atlanta, GA, USA) by means of the PTlink (Dako) for antigen unmasking. Immunohistochemistry was performed in the Autostainer PlusLink (Dako). Primary antibodies against active caspase 3 (diluted 1/150 for 30min, R&D Systems, Minneapolis, MN, USA), Ki67 (ready to use for 20min, Dako), CD45 (diluted 1/50 for 40 min, Dako) and CD19 (diluted 1/50 for 30 min, Dako) were used followed by secondary antibodies, goat anti rabbit horseradish peroxidase, goat anti mouse horseradish peroxidase and biotinylated mouse immunoglobulin G (MOM vector).
CD34-positive cell isolation and treatment
A detailed description of the CD34 þ cells isolation and treatment protocols are provided in the Supplementary Materials and methods.
Statistical analysis
A detailed description is provided in the Supplementary Materials and methods.
RESULTS
In vitro activity of LBH589 in ALL cells
We investigated the effect of treatment with LBH589 on six human-derived ALL cell lines corresponding to the most representative translocations in B-cell ALL (TOM-1 t(9,22)(q32;q11), REH t(12;21)(p12;q22), 697 t(1;19)(q23;p13), s.e.m. t(4;11)(q21;q23) and TANOUE t(8;14)(q24;q32)) and T-cell ALL (MOLT-4). In all analyzed ALL-derived cell lines except to TANOUE cell line, the IC 50 value of LBH589 were below 50 nM (Supplementary Figure S1) . In order to establish the optimal dose of LBH589, apoptosis was measured in TOM-1 and MOLT-4 after treatment with doses of 1 --100 nM for 48 h. At doses of 50 nM a significant increase in cell apoptosis was observed in all leukemic cell lines by detection of active caspase-3 (Figure 1a ), the increase in the 85-kDa fragment of poly(ADP ribose)polymerase by western blot or the increased detection of oligonucleosomal fragments. Nevertheless some differences were found between cell lines (Supplementary Figure S2) . Treatment with LBH589 also markedly inhibited proliferation of ALL cells with an inhibition close to 100% after 4 days (Figure 1b and Supplementary Figure S2 ). Inhibition of cell proliferation and increased apoptosis was associated with increased level of acetylation of histone H3 (AcH3) and histone H4 (AcH4) observed at doses of 50 nM of LBH589 but not at lower concentrations ( Figure 1c) . As an early marker of DNA damaged and activation of DNA repair genes, we examined the phosphorylation of H2AX, 20 which was found to be upregulated after treatment with LBH589 in a dose-dependent manner (Figure 1c ). This suggests a link between disruption of DNA repair and apoptosis induced by LBH589 and establishes a dose of 50 nM as the optimal dose in ALL cells.
Although apoptosis of ALL cells was detected between 12 and 24 h after treatment with LBH589, changes in acetylated H3 and H4 were detected as early as 2 h (Figures 1d and e) . Phosphorylation of H2AX was initially detected 12 to 24 h after in vitro treatment with LBH589 depending on the cell line employed (Figure 1e ). These results suggest that H3 and H4 acetylation precede DNA damaged and induction of apoptosis, which might indicate that inhibition of HDAC are likely to be responsible at least in part for LBH589-induced apoptosis and inhibition of cell proliferation.
In vivo effect of LBH589 in a subcutaneous mouse model of ALL The in vivo activity of LBH589 was initially examined in a subcutaneous ALL mouse model. The ALL cell lines TOM-1 and MOLT-4 were transplanted (1 Â 10 6 cell per animal) subcutaneously into the left flanks of 6-week-old female BALB/ cA-Rag2 À/À gc À/À . These cell lines develop into a rapidly growing tumor, as we have previously shown. 8 A group of healthy control BALB/cA-Rag2 À/À gc À/À mice were treated with increasing doses of LBH589 (1, 5, 10 and 20 mg/kg) administered i.p. in order to examine the maximum tolerated dose. Doses of 10 and 20 mg/kg were associated with splenomegaly, weight loss and central nervous system abnormalities (Supplementary Figure S3) , while no adverse effects were observed at doses of 1 and 5 mg/kg. Treatment with 5 mg/kg of LBH589 was initiated 24 h after injection of the leukemic cells and animals were monitored for 24 days. A significant inhibition of tumor growth was demonstrated in animals treated with LBH589 compared with control animals (Po0.01). Inhibition of leukemia cell growth was associated with an increase in the levels of acetylated H3 and H4 and an increase in phosphorylated H2AX as measured by western blot in the leukemic cells obtained after killing of mice ( Figure 2 ). These results suggest that LBH589 has a powerful antileukemic effect not only in vitro but also in vivo.
Characterization of an in vivo xenogeneic model of human ALL in immune-deficient mice In order to examine the efficacy of LBH589 in a more representative model, human ALL cells from patients with ALL were transplanted in BALB/cA-RAG2
. A total of 10 million cells from a patient with T-ALL (ALL-T1) and a patient with B-ALL (ALL-B1) (Table 1) were administered i.v. into the tail vein of immunodeficient mice. Animals were monitored by immunophenotyping in PB and/or BM. Mice died of leukemia or were killed when signs of overt leukemia were observed such as a percentage of human blasts higher than 80% in PB, weight lost higher than 20% and/or hunched posture. After being killed, spleen blasts were re-transplanted in secondary and tertiary recipients. After 2--5 generations, leukemic cells were frozen, thawed and re-injected into new immune-deficient mice with development of leukemia (Supplementary Figure S4) . Kinetics of engraftment of leukemic cells was monitored in PB and BM by phenotyping, whereas organ infiltration was analyzed by immunohistochemistry (supplementary Figures S5 and S6) . Differences in the disease development were observed between ALL-T1 and ALL-B1, with faster development of the disease in the case of ALL-T1 (Supplementary Figure  S5) . However, there were no differences in engraftment or development of the disease according to whether secondary or later recipients were analyzed.
To characterize the in vivo model further, conventional karyotyping as well as genotyping, gene expression and methylation arrays were performed in fresh cells from patients and samples obtained from mice at different generations (generation 1 --5). There were no significant differences in the genome, methylome or transcriptome between the original sample and the samples obtained after multiple generations, with the exception of minor differences between the original sample from ALL-T1 and the cells obtained after multiples transplants in mice, consistent with the presence of several clones at diagnosis with persistence of a single dominant clone after sequential transplants in vivo (Supplementary Figure S7) . LBH589 potentiates the in vivo effect of chemotherapy and prolongs survival in a mouse model of human ALL To determine the efficacy of LBH589 alone or in combination with drugs currently used for treatment of ALL, BALB/cA-RAG2 À/À gc À/À mice engrafted with ALL-T1 and ALL-B1 cells were treated with LBH589, vincristine and dexamethasone or a combination of LBH589 with vincristine --dexamethasone. A dose-finding study was previously performed in healthy BALB/cA-RAG2 À/À gc À/À mice establishing the following doses as the optimal non-toxic combination: 0.025 mg/kg (vincristine), 1 mg/kg (dexamethasone) and 5 mg/kg (LBH589) (Supplementary Figure S8) . The in vitro and in vivo hematopoietic toxicity associated with treatment with LBH589 or vincristine plus dexamethasone was not increased by the combination of the three drugs (Supplementary Figure S9) . Treatment was initiated when disease could be detected in PB by fluorescence-activated cell sorting (24 h after injection of cells for ALL-T1 and between day 17 and 21 after injection for ALL-B1). LBH589 was administered i.p. on days 1 --5, 8 --12 and 15 --19, vincristine i.v. on days 1, 8 and 21 and dexamethasone daily until day 21 i.p. (Figures 3a and 4a) and survival was compared in the four groups of animals: control (no treatment), LBH589, vincristine --dexamethasone and LBH589 --vincristine --dexamethasone.
Treatment with either LBH589 or vincristine --dexamethasone significantly reduced the percentage of leukemic cells in the PB (Figure 3b ) and BM (Figure 4b ), but the effect was significantly greater in animals treated with the combination of the HDACi and chemotherapy (Po0.01). Similarly, a significant reduction in spleen size was found after treatment with the combination of drugs (Figures 3c and 4c) , which was associated with an increase in acetylated H3 and H4 as well as in phosphorylation of H2AX in leukemic cells from the spleen of animals treated with LBH589 (Figures 3d and 4d) . Interestingly, treatment with LBH589 not only modified the acetylation of H3 and H4 but also induced significant changes in DNA methylation of leukemic cells obtained from the spleen of leukemic mice: ALL-T1 cells from mice treated with LBH589 clustered separately from untreated samples with hypomethylation of 59 genes and hypermethylation of 3 genes after treatment (Figure 3e and Supplementary Table S1 ). Similarly, ALL-B1 cells from mice treated with LBH589 clustered separately from untreated samples showing 217 genes hypomethylated and 54 hypermethylated genes (Figure 4 and Supplementary Table  S2 ). As an example, genes that are known to be hypermethylated in ALL such as the Wnt inhibitor SFRP4 involved in WNT pathway 11 became hypomethylated after treatment with LBH589. Finally, treatment with LBH589 and vincristine --dexamethasone prolonged survival of the leukemic mice in comparison with the control animals (Po0.05). Furthermore, there were statistically significant differences between animals treated with the combination of LBH589 --vincristine --dexamethasone compared with any of the other groups (Figures 3f and 4f) .
Treatment with LBH589 is associated with a decrease in the nuclear factor (NF)kB pathway activity and downregulation of its target CDK6 To gain insights into the mechanism of the anti-leukemic action of LBH589 in ALL, TOM-1 and MOLT-4 ALL cell lines were treated for analysis and the 930 differentially expressed genes, two different networks in which the NFkB pathway was involved were identified (genes related to cell death, cell-to-cell signaling, interaction and drug metabolism and metabolic disease). Both networks were further interconnected suggesting a potential role for the NFkB pathway in the anti-leukemic effect of LBH589 ( Figure 5b ). As shown in Figure 5c , a large number of known direct or indirect NFkB target genes (http://www.nf-kb.org), were significantly deregulated in T and B leukemia cells 21 including CDK6, a described target of NFkB and a gene previously described to be regulated by miRNAs in ALL. 8 No mutations of NFKB1, NFKB2 or CDK6 (data not shown) were found in ALL cell lines or in leukemic cells from ALL-B1 or ALL-T1.
In order to determine whether regulation of CDK6 in ALL, in addition to NFkB may be regulated by the expression of miRNAs, we compared the expression of 377 miRNAs after treatment of ALL cell lines with LBH589. Of the miRNAs differentially expressed after treatment with LBH589, a group of six miRNA (hsa-miR-124a, -139, -141, -145, -449b and -494) that have been shown to be putative regulators of CDK6 by the bioinformatic software miRGen (www.diana.pcbi.upenn.edu/miRGen.html) or found to regulate CDK6 by previous studies were upregulated in TOM-1 and MOLT-4 ( Figure 5d ). 8,22 --24 The analysis of CDK6 expression and its target Rb after treatment with LBH589 in vitro (cell lines) and in vivo (human leukemic blasts from the spleen) revealed a downregulation of CDK6 protein expression that was associated with a decrease in the levels of phosphorylated retinoblastoma (RB-P) in vitro and in vivo (Figures 5e and f) . These results suggest that treatment with LBH589 leads to inactivation of the CDK6-Rb oncogeneic pathway, frequently over expressed in ALL (Figure 5g ), through inactivation of the NFkB pathway and upregulation of miRNAs. Besides these pathways, LBH589 also induced an upregulation of the pro-apoptotic Bcl2-member BIM (BCL2L11), which has also been described to be silenced by epigenetic mechanisms in other B-cell malignancies such as Burkitt's lymphoma suggesting a C1  T1  T2  T3 C1  T1 T2 T3  C2  1 common mechanism of apoptotic blockade in lymphoid malignancies that can be reverted by LBH589. 25 
DISCUSSION
Despite significant progress in the treatment of patients with ALL, 460% of adults will succumb to their disease underlining the requirement for new therapeutic strategies for these patients. 26 The results of our study clearly establish the use of the HDACi LBH589 as a clinically useful drug with a synergistic effect with standard chemotherapy in patients with ALL. Furthermore, the development of a human leukemia mouse model could be very useful for investigating the efficacy of new drugs in ALL. The role of epigenetic regulation (hypermethylation of DNA and histone modifications) in the prognosis and pathogenesis of ALL has been clearly demonstrated by a number of groups. 8 --12,27 It provides a basis for the use of demethylating agents such as 5-aza-2'deoxycitidyne or decitabine in the treatment of ALL. 28 Although demethylating agents have been used and approved for different hematological malignancies such as AML and myelodysplastic syndromes, 29 the experience in patients with ALL is very limited. 30 On the other hand, the HDACi and specifically LBH589 (Panobinostat) have demonstrated preclinical activity in vitro and in vivo in a wide range of malignancies, such as subcutaneous and Hodgkin lymphomas, 31 multiple myeloma, 19 melanomas, 32 lung cancer, 33 colon cancer cell lines, 34 head and neck squamous cell carcinoma, 35 glioma cells 36 and some hematological malignances. 37 Similarly, the number of studies using LBH589 in ALL is very limited. 13, 38 An important finding from our study is that the anti-leukemic effect of LBH589 is observed in every cytogenetic subtype of ALL including both T and B-cell ALL as well as patients with Philadelphia-positive ALL. This is in agreement with recent studies, which demonstrate a synergistic effect of HDACi with tyrosine kinase inhibitors such as imatinib or dasatinib. 39 Although mechanisms related to acetylation of other proteins may be involved in the effect of LBH589, 40 the time-and dose-dependent studies performed suggest that activation of acetylation of H3 and H4 are early events in ALL (2 h after in vitro treatment). Interestingly, an increase in acetylation of H3 and H4 in leukemic cells was not only found in vitro but also in leukemic cells obtained from the spleen of treated mice.
The expression arrays performed after treatment with LBH589 provide an interesting insight into some of the putative pathways involved in the anti-leukemic effect induced by LBH589. The role of NFkB in the pathogenesis of certain subtypes of ALL such as T-ALL 21 or in the resistance to glucocorticoid has recently been described. 41 Similarly, cyclins and cdks, such as CDK6, have been implicated in the abnormal proliferation of ALL cells and establish these proteins as attractive targets. 8 Although we have not demonstrated a direct relation between the two pathways, our results do suggest that they may be related and that activation of CDK6-Rb may be driven by the activation of the NFkB pathway. The differential expression of miRNAs after LBH treatment (hsa-miR-494 and hsa-miR-449a have been previously described as regulating CDK6 expression) 22, 24 indicates that LBH589 has a pleitropic effect on many genes and miRNA that may act in concert to induce the inhibition of CDK6 and decreased phosphorylation of Rb protein, leading to inhibition of proliferation.
The use of human ALL cells to engraft immune-deficient mice has been previously exploited to assess the effect of new drugs in the treatment of ALL 42, 43 or even to predict the response of a specific patient to standard chemotherapy such as vincristine and dexamethasone. 44 However, our approach differs from those of previous studies as we have developed a model that can be transplanted into multiple generations of animals without significant changes either in their genetic or epigenetic makeup. This makes our model particularly appropriate for long-term studies and for comparing different therapies. Whether this model is able to predict the efficacy of certain treatments in patients with ALL is yet to be demonstrated but the possibility of monitoring the disease in the PB and BM is advantageous for testing new therapeutic strategies.
Although the combination of LBH589 with vincristine and dexamethasone was able to prolong survival, the mice eventually succumbed to their disease, consistent with the pattern we observed in patients with ALL, in which multiple courses of induction, consolidation and maintenance are required to treat the disease effectively. It is also plausible that this model may be helpful for testing treatments designed to mirror human ALL therapy, which would contribute significantly to the development of new therapies.
In conclusion, our results show that the addition of the HDACi LBH589 may form the basis of a novel treatment of patients with ALL as well as suggesting new candidate signal transduction pathways involved in the pathogenesis of ALL, such as CDK6, thereby providing a rationale for the use of CDK6 inhibitors in a combination of epigenetic drugs and standard therapy. The development of our human leukemic mouse model should facilitate the assessment of the efficacy of these new therapies for ALL, eventually enabling their clinical evaluation in ALL patients.
